galactosaemia

News

Warning letter adds to Applied Tx run of bad news

Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week.

News

Applied Tx craters as FDA rejects lead product candidate

Applied Therapeutics plummets after the FDA turns down its marketing application for govorestat as a treatment for galactosaemia

News

Applied Therapeutics slumps as FDA seeks more data on lead d...

Shares in Applied Therapeutics slumped today after it said it would have to delay a US filing for its lead drug programme AT-007, following an FDA request for more data.

Warning letter adds to Applied Tx run of bad news

Applied Tx craters as FDA rejects lead product candidate

Applied Therapeutics slumps as FDA seeks more data on lead d...

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks